Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3)
and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor
(FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced
for the treatment of AIDS. The molecular designing is the first stage in production of
Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important
in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal
antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in
clinic is in progress and among these medications Etanercept is the most effective in therapy.
At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion
proteins which are in pre-clinical and clinical development. In this article, we review the molecular
and biological characteristics of Fc-fusion proteins and then further discuss the features
of novel therapeutic Fc-fusion proteins.
Keywords: Fc-fusion proteins, immunotherapy, FcRn, antibody, Fc region.
Rights & PermissionsPrintExport